Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

Henry M. Jackson Foundation for the Advancement of Military Medicine

Status and phase: Completed; Phase 2

Conditions: Primary Peritoneal Cancer; Ovarian Cancer

Treatments: Drug: imatinib mesylate by mouth; Drug: Gemcitabine Intravenous

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00928642

CSTI571BUS241

MAMC#206126

Details and patient eligibility

About

This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study will continue as long as the patient's tumors shrink or remain stable and as long as the patient is able to tolerate the study drug. The follow-up portion of the study will last for 5 years.

Full description

Each 21 day period will be considered a cycle. Disease status will be assessed with a Cancer Antigen (CA)-125 prior to the start of each new cycle with an assessment of measurable diseased by either CT or MRI every 6 weeks. Treatment will continue until disease progression, unacceptable toxicities, or the patient elects to withdraw from the study. All patients will be followed until disease progression or study withdraw. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years, unless consent is withdrawn.

Enrollment: 8 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients 18 years of age or greater
• Histologically documented diagnosis of ovarian cancer or primary peritoneal cancer. Histological subtypes include: mucinous tumor, serous tumor, endometrioid tumor, and other histologies including clear cell and undifferentiated epithelial tumors.
• At least one measurable site of disease (as defined by Southwestern Oncology Group Solid Tumor Response Criteria) or other response assessment criteria, as appropriate.
• Patients must have relapsed after receiving at least one prior platinum-based chemotherapy.
• Performance status of 0, 1, 2, (ECOG)
• Adequate end organ function: Total bilirubin < 1.5 x ULN, SGOT and SGPT < 2.5 UNL, creatinine < 1.5 x UNL, ANC > 1.5 x 109/L, platelets > 100 x 109/L.
• Patients will most likely have had their ovaries removed at the time off initial surgery. If any subjects are of childbearing potential at the time of entry, they must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Subjects of reproductive potential must agree to employ and effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of the study drug.
• Written, voluntary informed consent.
• Patients must be eligible for care at a military medical treatment facility.

Exclusion criteria

• Patient has received prior treatment with Gemzar.
• Patient has received any other investigational agents within 28 days of the first day of study drug dosing.
• Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is neither currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
• Patient with Grade III/IV cardiac problems as defined but the New York Heart Association Criteria.
• Patients who are pregnant or breast-feeding.
• Patient has a severe and/or uncontrolled medical disease (i,e. uncontrolled diabetes, uncontrolled chronic renal disease, or active uncontrolled infection).
• Patient has a known untreated or progressive brain metastasis.
• Patient has known chronic liver diseases (i.e. chronic active hepatitis, and cirrhosis.
• Patient has a known diagnosis of human immunodeficiency virus (HIV infection ).
• Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry, unless the disease is rapidly progressing..
• Patient previously received radiotherapy to greater than or equal to 25% of the bone marrow.
• Patient had a major surgery within 2 weeks prior to study entry.
• Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

Oral Imatinib plus intravenous gemcitabine

Experimental group

Description:

All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle. All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. . All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy.

Treatment:

Drug: Gemcitabine Intravenous

Drug: imatinib mesylate by mouth